EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

Xue Tang, Jing-Jing Sun, Zhi Wan, Xiao-Yu Jing, Xia Guo iD, Ju Gao

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Xue Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Histiocytosis, Langerhans-Cell, Protein Kinase Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Mitogen-Activated Protein Kinases. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medical Research Project of Sichuan Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Langerhans cell histiocytosis (LCH) is a rare, heterogeneous inflammatory myeloid neoplasm. This study focuses to summarize real‐world experiences of using mitogen‐activated protein kinase (MAPK) inhibitors in managing pediatric LCH. Thirty‐six children with LCH received vemurafenib ( n = 11), dabrafenib ( n = 19), or trametinib ( n = 6), either as monotherapy ( n = 24) or combined with chemotherapy ( n = 12). The median Disease Activity Score declined from 5 at baseline to 1 after 3 months of MAPK inhibitor therapy ( p < .0001). Elevated interleukin‐2 receptor (IL‐2R) and tumor necrosis factor‐α (TNF‐α) levels were observed in 90.1% and 81.8% of patients, respectively. Median IL‐2R and TNF‐α levels decreased from 1212 U/mL and 15 ρg/mL at baseline to 494 U/mL and 4.18 ρg/mL at 3 months ( p < .0001, p = .002), with no significant differences between MAPK inhibitor alone and combined with chemotherapy groups ( p = .7791, p = .7503). The objective response rate at 3 months was 94.4% (34/36). At last follow‐up, 20 patients had no active disease (NAD); 13 had NAD with residual diabetes insipidus and/or sclerosing cholangitis; 1 had NAD with neurodegeneration; and 2 died of progressive disease. Among 13 patients who discontinued treatment, relapse occurred more frequently in the monotherapy group (75%) than in the combination group (20%), but the difference was not statistically significant ( p = .103). [Correction added on 07 February 2026, after first online publication: The p value has been revised from .047 to .103.]. Grade ≥3 adverse events occurred in 11.1% and resolved with dose adjustment. MAPK inhibitors are effective and well tolerated in pediatric LCH. Combination therapy may reduce relapse risk. Further prospective studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histiocytosis, Langerhans-CellProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsMitogen-Activated Protein KinasesHumansMaleFemaleChildChild, PreschoolAdolescentInfantPyridonesPyrimidinonesVemurafenibImidazolesOximesTreatment OutcomeRecurrenceRetrospective StudiesTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

Langerhans cell histiocytosisMAPKchemotherapyoutcomespediatricsreal world

Substanzen

trametinibProtein Kinase InhibitorsdabrafenibPyridonesPyrimidinonesVemurafenibImidazolesOximesMitogen-Activated Protein KinasesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, Sichuan, China.

ORCID-Profile: Xia Guo

Förderung

  • Medical Research Project of Sichuan Medical Association

Zitieren

APA

Tang, X., Sun, J. J., Wan, Z., Jing, X. Y., Guo, X., & Gao, J. (2025). Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study. International Journal of Cancer. https://doi.org/10.1002/ijc.70300

Vancouver

Tang X, Sun JJ, Wan Z, Jing XY, Guo X, Gao J. Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study. International Journal of Cancer. 2025. doi:10.1002/ijc.70300

BibTeX
@article{Tang2025,
  author = {Tang, Xue and Sun, Jing-Jing and Wan, Zhi and Jing, Xiao-Yu and Guo, Xia and Gao, Ju},
  title = {Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70300}
}
Kostenlos starten →